Gastric Cancer

, Volume 10, Issue 4, pp 221–227 | Cite as

The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab

  • Francesca Di Fabio
  • Carmine Pinto
  • Fabiola L. Rojas Llimpe
  • Stefano Fanti
  • Paolo Castellucci
  • Ciro Longobardi
  • Vita Mutri
  • Chiara Funaioli
  • Francesca Sperandi
  • Stefania Giaquinta
  • Andrea A. Martoni
Original article

Abstract

Background

The aim of the study was to evaluate whether the therapy-induced reduction of the 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) maximum standardized uptake value in patients with advanced gastric adenocarcinoma treated with chemotherapy plus cetuximab could predict the objective response and outcome early during the treatment.

Methods

The study was performed as a part of a phase II trial evaluating cetuximab plus the leucovorin/5-fluorouracil/irinotecan (FOLFIRI) regimen. The objective response was evaluated according to the response evaluation criteria in solid tumors (RECIST) every 6 weeks. The early metabolic response evaluated by 18F-FDG-PET was assessed according to our own evaluated cutoff value (<35%) after receiver operating characteristic (ROC) analysis.

Results

Twenty of 22 patients had positive baseline 18F-FDG-PET. The best RECIST response was: complete response (CR), 3; partial response (PR), 9; stable disease (SD), 8. Twelve patients (60%) were classified as metabolic responders and 8 (40%) as nonresponders. At the median follow-up time of 11 months, median time to disease progression (TTP) and overall survival (OS) for early metabolic responders versus nonresponders were 11 versus 5 months (P = 0.0016) and 16 versus 6 months (P = 0.1493), respectively.

Conclusion

The early metabolic response evaluated by 18F-FDG-PET predicted the clinical outcome in this series of patients with advanced gastric cancer treated with chemotherapy plus cetuximab.

Key words

PET Advanced gastric adenocarcinoma Cetuximab 

References

  1. 1.
    Kamangar, F, Dores, GM, Anderson, WF 2006Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the worldJ Clin Oncol24213750PubMedCrossRefGoogle Scholar
  2. 2.
    Hansson, LE, Sparen, P, Nyren, O 1999Survival in stomach cancer is improving: results of a nationwide population-based Swedish studyAnn Surg2301629PubMedCrossRefGoogle Scholar
  3. 3.
    Kelley, JR, Duggan, JM 2003Gastric cancer epidemiology and risk factorsJ Clin Epidemiol5619PubMedCrossRefGoogle Scholar
  4. 4.
    Wagner, AD, Grothe, W, Haerting, J, Kleber, G, Grothey, A, Fleig, WE 2006Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate dataJ Clin Oncol2429039PubMedCrossRefGoogle Scholar
  5. 5.
    Shah, MA, Ramanathan, RK, Ilson, DH, Levnor, A, D'Adamo, D, O'Reilly, E,  et al. 2006Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaJ Clin Oncol2452016PubMedCrossRefGoogle Scholar
  6. 6.
    Pinto, C, Di Fabio, F, Siena, S, Cascinu, S, Rojas Llimpe, FL, Ceccarelli, C,  et al. 2007Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX Study)Ann Oncol185107PubMedCrossRefGoogle Scholar
  7. 7.
    Mochiki, E, Kuwano, H, Katoh, H, Asao, T, Oriuchi, N, Endo, K 2004Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancerWorld J Surg2824753PubMedCrossRefGoogle Scholar
  8. 8.
    Rosenbaum, SJ, Stergar, H, Antoch, G, Veit, P, Bockisch, A, Kühl, H 2006Staging and follow-up of gastrointestinal tumors with PET/CTAbdom Imaging312535PubMedCrossRefGoogle Scholar
  9. 9.
    Kim, SK, Kang, KW, Lee, JS, Kim, HK, Chang, HJ, Choi, JY,  et al. 2006Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancerEur J Nucl Med Mol Imaging3314855PubMedCrossRefGoogle Scholar
  10. 10.
    Kostakoglu, L, Goldsmith, SJ 200318F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinomaJ Nucl Med4422439PubMedGoogle Scholar
  11. 11.
    Kostakoglu, L, Goldsmith, SJ 2004PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagusJ Nucl Med455668PubMedGoogle Scholar
  12. 12.
    Weber, WA 2005Use of PET for monitoring cancer therapy and for predicting outcomeJ Nucl Med4698395PubMedGoogle Scholar
  13. 13.
    Rousseau, C, Devillers, A, Sagan, C, Ferre, L, Bridji, B, Campion, L,  et al. 2006Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomographyJ Clin Oncol24536672PubMedCrossRefGoogle Scholar
  14. 14.
    Weber, WA, Ott, K, Becker, K, Dittler, HJ, Helmberger, H, Avril, NE,  et al. 2001Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imagingJ Clin Oncol19305865PubMedGoogle Scholar
  15. 15.
    Ott, K, Fink, U, Becker, K, Stahl, A, Dittler, HJ, Busch, R,  et al. 2003Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trialJ Clin Oncol21460410PubMedCrossRefGoogle Scholar
  16. 16.
    Ott, K, Weber, WA, Lordick, F, Becker, K, Busch, R, Hermann, K,  et al. 2006Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junctionJ Clin Oncol2446928PubMedCrossRefGoogle Scholar
  17. 17.
    Fanti, S, Franchi, R, Battista, G, Monetti, N, Canini, R 2005PET and PET-CT. State of the art and future prospectsRadiol Med11115Google Scholar
  18. 18.
    Therasse, P, Arbuck, SG, Eisenhauer, EA, Wanders, J, Kaplan, RS, Rubistein, L,  et al. 2000New guidelines to evaluate the response to treatment in solid tumorsJ Natl Cancer Inst9220516PubMedCrossRefGoogle Scholar
  19. 19.
    Metz, CE 1989Some practical issues of experimental design and data analysis in radiologic ROC studiesInvest Radiol2423445PubMedCrossRefGoogle Scholar
  20. 20.
    Kaplan, EL, Meier, P 1958Nonparametric estimation of incomplete observationsJ Am Stat Assoc5345781CrossRefGoogle Scholar
  21. 21.
    Becker, JC, Muller-Tidow, C, Serve, H, Domschke, W, Pohle, T 2006Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapyWorld J Gastroenterol123297305PubMedGoogle Scholar
  22. 22.
    Schelling, M, Avril, N, Nährig, J, Kuhn, W, Römer, W, Sattler, D,  et al. 2000Positron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancerJ Clin Oncol18168995PubMedGoogle Scholar
  23. 23.
    Smith, IC, Welch, AE, Hutcheon, AW, Miller, ID, Payne, S, Chilcott, F,  et al. 2000Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapyJ Clin Oncol18167688PubMedGoogle Scholar
  24. 24.
    Kostakoglu, L, Coleman, M, Leonard, JP, Kuji, I, Zoe, H, Goldsmith, SJ 2002PET predicts prognosis after one cycle of chemotherapy in aggressive lymphoma and Hodgkin's diseaseJ Nucl Med43101827PubMedGoogle Scholar
  25. 25.
    Brun, E, Kjellen, E, Tennvall, J, Ohlsson, T, Sandell, A, Perfekt, R,  et al. 2002FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinomaHead Neck2412735PubMedCrossRefGoogle Scholar
  26. 26.
    Weber, WA, Petersen, V, Schmidt, B, Tyndale-Hines, L, Link, T, Peschel, C,  et al. 2003Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose useJ Clin Oncol2126517PubMedCrossRefGoogle Scholar
  27. 27.
    Ott, K, Weber, WA, Fink, U, Helmberger, H, Becker, K, Stein, HJ,  et al. 2003Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardiaWorld J Surg2710359PubMedCrossRefGoogle Scholar

Copyright information

© International and Japanese Gastric Cancer Association 2007

Authors and Affiliations

  • Francesca Di Fabio
    • 1
  • Carmine Pinto
    • 1
  • Fabiola L. Rojas Llimpe
    • 1
  • Stefano Fanti
    • 2
  • Paolo Castellucci
    • 2
  • Ciro Longobardi
    • 1
  • Vita Mutri
    • 1
  • Chiara Funaioli
    • 1
  • Francesca Sperandi
    • 1
  • Stefania Giaquinta
    • 1
  • Andrea A. Martoni
    • 1
  1. 1.Medical Oncology UnitS. Orsola-Malpighi HospitalBolognaItaly
  2. 2.Nuclear Medicine UnitS. Orsola-Malpighi HospitalBolognaItaly

Personalised recommendations